N@N

Proteonomix, Inc: Proteonomix, Inc. (PROT) Announces the Appointment of Steven Byle to Its Board of Directors

^{Published on 2009-01-05 07:08:59, Last Modified on 2009-01-05 07:09:29 - Market Wire}
 

MOUNTAINSIDE, NJ--(Marketwire - January 5, 2009) - Proteonomix, Inc. (PINKSHEETS: [ PROT ]) announces the appointment of Steven Byle to its Board of Directors effective January 15, 2009.

Mr. Byle is a successful entrepreneur, engineer and patent attorney with a track record in domestic and international industry. He is presently Vice-President of Technology for Dockwise, B.V., a public, international company with nearly $500 million in annual revenue in the energy industry where he is charge of its R& D program and intellectual property portfolio. He has studied and taught in China and speaks fluent Chinese.

Michael Cohen, CEO of Proteonomix, stated: "We welcome Steven to our board of directors. His extensive background both in intellectual property and corporate development shall enhance our company's growth and development in its commercialization stage."

[ About Proteonomix, Inc. ]

Proteonomix, Inc. is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. It is developing an intellectual property portfolio in the areas of therapeutics and cosmetics. Its research and development program has demonstrated results with more than ten patent applications and multiple products ready to enter their respective markets. Proteonomix has facilities at a number of academic institutions. Its subsidiary, Proteoderm, has developed a line of anti-aging cosmetics. For more information, please visit [ www.proteonomix.com ] or [ www.proteoderm.com ] and [ www.pinksheets.com ].

"Safe Harbor Statement"

Under the Private Securities Litigation Reform Act of 1995, statements herein relating to the Company's expectations are forward-looking statements. The anticipated results, including the entering into an agreement reflecting the terms of the letter of intent and performance pursuance thereto may not occur.